SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is an orally active small molecule inhibitor of both the Src and Abl, and was approved for the treatment of imatinib refractory chronic myelogenous leukemia and bcr-abl positive acute lymphoblastic leukemia [20].